Prophylactic effect of riboflavin on pediatric migraine: a randomized, double-blind, placebo-controlled trial
Talebian A, Soltani B, Banafshe HR, Moosavi GA
Published in Electronic Physician
Methodology
Randomized, double-blind, placebo-controlled trial of low-dose vs high-dose riboflavin vs placebo in 90 children with migraine over 12 weeks.
Key Findings
High-dose riboflavin significantly reduced headache frequency and mean duration versus placebo, while low-dose riboflavin did not; neither dose reduced headache intensity.
Conclusions
High-dose riboflavin is a safe and inexpensive prophylactic option in children, but it does not reduce attack intensity and low doses are ineffective.
Limitations
Single-centre, modest sample, pediatric population may not generalize to adults, short 12-week follow-up.
Supplements Studied
There was a significant decrease of migraine frequency (p=0.000) and mean duration (p=0.000) in the high-dose group compared with the placebo group.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Kashan University of Medical Sciences
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.